GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.53 (+0.62%)

Growth Price

Undervalued by 91.02%

Stability Price

Overvalued by 40.17%

Company Metrics

  • P/E 7.33
  • P/S 3.46
  • P/B 8.58
  • EPS 11.71
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.88 / 2.2%
  • Avg. Vol. 10.80M
  • Shares 1.52B
  • Market Cap. 114.30B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Better Buy: Gilead Sciences Inc. vs. Johnson & Johnson
Motley Fool - May 26, 2016
They're two of the biggies in healthcare. Gilead Sciences Inc. (NASDAQ:GILD) grew to become the largest biotech in the world over the last decade on the back of its HIV and hepatitis C franchises.
Gilead Sciences -- Strong Buy Despite Management Shakeup: Barrons - Bidness ETC
Gilead Brings Top Exec Out of Retirement - Pharmaceutical Executive (press release) (registration) (blog)
Analysts Cautious on Valeant Pharmaceuticals Intl Inc (VRX) and Gilead ...
Smarter Analyst - May 26, 2016
It's not all bullish in the biotech sector. Analysts remains bearish and neutral on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Gilead Sciences, Inc. (NASDAQ:GILD), respectively, as Valeant faces legal battles and Gilead gains new FDA dosing ...
Gilead's Profits Won't Disappear Overnight
Seeking Alpha - May 27, 2016
Gilead is an attractive, low price-to-earnings, biopharmaceutical company with a healthy growing dividend. Gilead recently missed earnings expectations, and the stock sold-off as many investors bought into the narrative that it's now a company in decline.
EU regulators recommend approving Gilead's new hepatitis C drug - Reuters
Company Update (NASDAQ:GILD): Gilead Sciences, Inc. Receives Positive CHMP ...
Smarter Analyst - May 27, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency(EMA), has adopted a positive opinion on the company's Marketing Authorization ...
Gilead Sciences, Inc HCV Dominance Set To Rise: European Ad Comm Backs Epclusa - Bidness ETC
Trend Analysis Report: Verizon Communications Inc. (NYSE:VZ), Gilead Sciences ... - NYSE Journal (press release)
Can Gilead Sciences, Inc. (GILD) Lead the Undisputed HCV Market?
Business Finance News - May 28, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) has gained a positive opinion for Epclusa from the Committee for Medicinal Products for Human Use (CHMP), a European Medicines Agency (EMA) committee for Marketing Authorization Application (MAA).
How Many Gilead Sciences, Inc. (NASDAQ:GILD)'s Analysts Are Bullish? - Franklin Independent
Gilead Sciences, Biogen, Jazz Pharma Get Subpoenas Regarding Relationships ... - Sonoran Weekly Review
Gilead Sciences, Inc. (GILD) Has the Key to Double HIV Revenues, Says Leerink
TCC - May 27, 2016
Equity research firm Leerink Partners has updated its thesis on Gilead Sciences, Inc.'s (NASDAQ:GILD) HIV business.
What to Watch at ASCO: Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG) - Smarter Analyst
Analysts Advise About Gilead Sciences, Inc. (NASDAQ:GILD) - Zergwatch
Analyst Downgrades: NetApp Inc., Pure Storage Inc, and Gilead Sciences, Inc.
Schaeffers Research (blog) - May 26, 2016
Analysts are weighing in on software maker NetApp Inc. (NASDAQ:NTAP), data storage specialist Pure Storage Inc (NYSE:PSTG), and biotech stock Gilead Sciences, Inc. (NASDAQ:GILD). Here's a quick roundup of today's bearish brokerage notes on NTAP, ...
Maxim Adjusts Estimates for Gilead Sciences, Inc. (GILD); Here's Why
Smarter Analyst - May 20, 2016
Maxim analyst Jason McCarthy reiterated a Hold rating on shares of pharmaceutical giant Gilead Sciences, Inc (NASDAQ:GILD), after discussing with GILD management about the launch of Genvoya and other HIV products.
Here's Why the Street Remains Bullish on Gilead Sciences, Inc (NASDAQ:GILD ... - TCC
Gilead Sciences, Inc. (NASDAQ:GILD) Analyst Research Summary: - Zergwatch
Why Gilead Sciences, Inc. (GILD), Stericycle Inc (SRCL) and Western Digital ... - Apr 29, 2016
Still worried about weakness that materialized earlier this week, and less than impressed by April's dwindling PMI reading, stocks started and finished the last trading day of the week and the month in the red.
Gilead Sciences' (GILD) Hold Rating Reiterated at Morgan Stanley - Web Breaking News
Gilead Sciences (GILD) is Reiterated by UBS to Buy, Lowers Price Target to $ 118 - Market Digest
Gilead Sciences Inc. (GILD) Pops 3.47% for May 24 - May 24, 2016
One of the S&P 500's big winners for Tuesday May 24 was Gilead Sciences Inc. (GILD) as the company's stock climbed 3.47% to $86.22 on volume of 13.13 million shares.